Overview of the drug development pipeline for optic neuritis
Optic neuritis is an inflammation that damages the optic nerve, which is a bundle of nerve fibers that helps in transmitting visual information from the eye to the brain. The inflammation frequently causes temporary vision loss, which mostly happens in only one eye. Optic neuritis can happen through a nerve disease or from some infection such as measles and tuberculosis. Multiple sclerosis, a chronic disease, can also lead to the inflammation and damage the optic nerve, which can lead to optic neuritis. Consequently, the rising incidences of optic neuritis is expected to boost the drug development for optic neuritis.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for optic neuritis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of optic neuritis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Biogen
- Bionure Farma
- Commence Bio
- LipoCure
- MedDay
Therapeutic assessment of the drug development pipeline for optic neuritis by route of administration
- Intravenous
- Oral
- Intranasal
- Parenteral
The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for optic neuritis by therapy
- Monotherapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for optic neuritis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for optic neuritis?
- What are the companies that are currently involved in the development of drug molecules for optic neuritis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.